Morpholino

MO1-vcana

ID

ZDB-MRPHLNO-120404-6

Name

MO1-vcana

Previous Names

versican-MO (1)

Target

vcana (1)

Sequence

5' - CTGAAACACCCATGGGAGTGGACAT - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO1-vcana

No data available

Phenotype

Phenotype resulting from MO1-vcana

Phenotype	Fish	Figures
blood protein decreased amount, abnormal	lri500Tg + MO1-vcana	Fig. 4 from Müller-Deile et al., 2016
endocardial cushion morphology, abnormal	AB + MO1-vcana	Fig. 8 from Chen et al., 2012
otic vesicle protrusion extracellular matrix organization decreased process quality, abnormal	hm40Tg + MO1-vcana	Fig. 4 from Mori et al., 2024
pericardium edematous, abnormal	lri500Tg + MO1-vcana	Fig. 4 from Müller-Deile et al., 2016
pronephric glomerulus lacks parts or has fewer parts of type glomerular basement membrane glomerular endothelium fenestra, abnormal	AB + MO1-vcana	Fig. 6 from Müller-Deile et al., 2016
pronephric podocyte decreased length, abnormal	AB + MO1-vcana	Fig. 6 from Müller-Deile et al., 2016
pronephric podocyte increased width, abnormal	AB + MO1-vcana	Fig. 6 from Müller-Deile et al., 2016

Phenotype of all Fish created by or utilizing MO1-vcana

Phenotype	Fish	Conditions	Figures
pronephric glomerulus lacks parts or has fewer parts of type glomerular basement membrane glomerular endothelium fenestra, abnormal	AB + MO1-vcana	standard conditions	Fig. 6 from Müller-Deile et al., 2016
pronephric podocyte decreased length, abnormal	AB + MO1-vcana	standard conditions	Fig. 6 from Müller-Deile et al., 2016
endocardial cushion morphology, abnormal	AB + MO1-vcana	standard conditions	Fig. 8 from Chen et al., 2012
pronephric podocyte increased width, abnormal	AB + MO1-vcana	standard conditions	Fig. 6 from Müller-Deile et al., 2016
atrioventricular canal snai1b expression absent, abnormal	WT + MO1-vcana	chemical treatment: amiodarone	Fig. 2 from Lee et al., 2015
atrioventricular canal cdh5 expression increased distribution, abnormal	WT + MO1-vcana	chemical treatment: amiodarone	Fig. 2 from Lee et al., 2015
otic vesicle protrusion extracellular matrix organization decreased process quality, abnormal	hm40Tg + MO1-vcana	standard conditions	Fig. 4 from Mori et al., 2024
pericardium edematous, abnormal	lri500Tg + MO1-vcana	standard conditions	Fig. 4 from Müller-Deile et al., 2016
blood protein decreased amount, abnormal	lri500Tg + MO1-vcana	standard conditions	Fig. 4 from Müller-Deile et al., 2016
semicircular canal morphogenesis decreased process quality, abnormal	hm40Tg + MO1-vcana + MO1-vcanb	control	Fig. 3 from Mori et al., 2024
otic vesicle lateral protrusion decreased length, abnormal	hm40Tg + MO1-vcana + MO1-vcanb	control	Fig. 3 from Mori et al., 2024
otic vesicle anterior protrusion decreased length, abnormal	hm40Tg + MO1-vcana + MO1-vcanb	control	Fig. 3 from Mori et al., 2024
otic vesicle posterior protrusion decreased length, abnormal	hm40Tg + MO1-vcana + MO1-vcanb	control	Fig. 3 from Mori et al., 2024

Citations